ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

The BCL-2 inhibitor Venetoclax is a promising agent for the treatment of acute myeloid leukemia (AML). However, many patients are refractory to Venetoclax, and resistance develops quickly. ATP-binding cassette (ABC) transporters mediate chemotherapy resistance but their role in modulating the activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebner, Jessica, Schmoellerl, Johannes, Piontek, Martin, Manhart, Gabriele, Troester, Selina, Carter, Bing Z., Neubauer, Heidi, Moriggl, Richard, Szakács, Gergely, Zuber, Johannes, Köcher, Thomas, Andreeff, Michael, Sperr, Wolfgang R., Valent, Peter, Grebien, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509209/
https://www.ncbi.nlm.nih.gov/pubmed/37726279
http://dx.doi.org/10.1038/s41467-023-41229-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509209/
https://www.ncbi.nlm.nih.gov/pubmed/37726279
http://dx.doi.org/10.1038/s41467-023-41229-2

Ejemplares similares